Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma Intervention: Drug: Orelabrutinib Sponsor: Ruijin Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials